2.19

0.45% -0.01

After Hours: 2.15 -0.04 -1.83%

Spero Therapeutics Inc (SPRO)

Overview News Price History Option Chain Financials Discussions Forecast

Spero Therapeutics Inc stock is traded at $2.19, with a volume of 350.53K. It is down -0.45% in the last 24 hours and down -22.34% over the past month. Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Previous Close:

$2.20

Open:

$2.17

24h Volume:

350.53K

Relative Volume:

0.37

Market Cap:

$126.80M

Revenue:

$54.77M

Net Income/Loss:

$15.24M

P/E Ratio:

8.9901

EPS:

0.2436

Net Cash Flow:

$7.24M

1W Performance:

-3.10%

1M Performance:

-22.34%

6M Performance:

-12.75%

1Y Performance:

-24.74%

1-Day Range:

$2.15

$2.205

1-Week Range:

$2.15

$2.285

52-Week Range:

$1.80

$3.22

Spero Therapeutics Inc Stock (SPRO) Company Profile

Name

Spero Therapeutics Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

857-242-1600

Address

675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA

Employee

Twitter

@spero_tx

Next Earnings Date

2026-08-11

Latest SEC Filings

SPRO's Discussions on Twitter

Compare SPRO vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SPRO Spero Therapeutics Inc	2.19	127.96M	54.77M	15.24M	7.24M	0.2436
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-20-24	Downgrade	Evercore ISI	Outperform → In-line
Sep-23-22	Upgrade	Evercore ISI	In-line → Outperform
Oct-01-21	Downgrade	Oppenheimer	Outperform → Perform
Jan-22-21	Reiterated	H.C. Wainwright	Buy
Dec-16-20	Initiated	Berenberg	Buy
Sep-29-20	Initiated	Evercore ISI	Outperform
Nov-05-19	Reiterated	H.C. Wainwright	Buy
Sep-09-19	Initiated	Janney	Buy
Feb-09-18	Initiated	Cantor Fitzgerald	Overweight
Nov-27-17	Initiated	BofA/Merrill	Neutral
Nov-27-17	Initiated	Oppenheimer	Outperform
Nov-27-17	Initiated	Stifel	Buy

View All

Spero Therapeutics Inc Stock (SPRO) Latest News

Jun 29, 2026

Spero Therapeutics, Inc.(NasdaqGS: SPRO) added to Russell 3000E Growth Benchmark - marketscreener.com

Jun 29, 2026

Spero Therapeutics, Inc.(NasdaqGS: SPRO) added to Russell 3000E Index - marketscreener.com

Jun 29, 2026

Spero Therapeutics, Inc.(NasdaqGS: SPRO) added to Russell Microcap Index - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Kailera Appoints New Chief Corporate Affairs Officer - Intellectia AI

Jun 28, 2026

Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell Microcap Growth Benchmark Index - marketscreener.com

Jun 28, 2026

Jun 26, 2026

Form 4 Spero Therapeutics Inc For: 25 June By Investing.com - Investing.com South Africa

Jun 26, 2026

Spero Therapeutics, Inc. Actuals & Estimates (NASDAQ:SPRO) - TradingView

Jun 26, 2026

Spero Therapeutics, Inc. Actuals & Estimates (BOATS:SPRO) - TradingView

Jun 26, 2026

Jun 25, 2026

Spero Therapeutics (SPRO) director awarded RSUs and 20,000-share option - Stock Titan

Jun 25, 2026

Spero Therapeutics (SPRO) director receives RSU and stock option awards - Stock Titan

Jun 25, 2026

Spero Therapeutics (SPRO) director receives 10,000 RSUs and 20,000-share option grant - Stock Titan

Jun 25, 2026

Spero Therapeutics (SPRO) director awarded RSUs and stock options - Stock Titan

Jun 25, 2026

Spero Therapeutics (SPRO) grants director RSUs and 20,000 stock options - Stock Titan

Jun 25, 2026

Equity awards to Spero (NASDAQ: SPRO) director Scott Jackson - Stock Titan

Jun 25, 2026

Spero Therapeutics (SPRO) director receives RSU and 20,000-share option grant - Stock Titan

Jun 25, 2026

Spero Therapeutics Expands Stock Incentive Plan and Authorization - TipRanks

Jun 25, 2026

Spero Therapeutics (NASDAQ: SPRO) doubles share authorization and adopts 2026 stock plan - Stock Titan

Jun 25, 2026

SPRO Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Spero Therapeutics (SPRO) Short Interest & Short Float | Updated Jun 2026 - MarketBeat

Jun 25, 2026

Jun 23, 2026